Extracellular vesicles
Phase 1Biologic
Extracellular vesicles is one of 35 biologic programs targeting Extracellular Vesicles. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
49 competitors in Diabetic Foot
#DrugCompanyPhaseTrials
1Desferal
Jazz PharmaceuticalsApproved
Remodulin
United TherapeuticsApproved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Januvia
ZZydus Therapeutics Inc.
Approved
Caverject
VViatris Specialty LLC
Approved
Sporanox
SSebela Pharmaceuticals Development LLC
Approved
Inomax
MMallinckrodt
Approved
Tobrex
VViatris Specialty LLC
Approved
Nitrostat
VViatris Specialty LLC
Approved
Acetadote
AArbor Pharmaceuticals, Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Extracellular vesicles. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 1[1]
- Company
- UUniversity of Jordan